Analytical Method Development and Validation of Abacavir and Emtricitabine by UV and Visible Spectrophotometry
Future Journal of Pharmaceuticals and Health Sciences · 04.04.2026 · 6 (2) · 14-24
DOI: 10.26452/fjphs.v6i2.554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 04.04.2026. Verfasst von {"name":"Kommala Pavithra","email":"harichandana.1007@gmail.com","affiliation und 7 weiteren Autor:innen.
Abstract (Originalsprache)
The present study was carried out with the objective of developing and validating a simple, accurate, precise, and cost - effective UV – Visible spectrophotometric method for the simultaneous estimation of Abacavir and Emtricitabine in bulk drug substances and combined tablet dosage forms. Both drugs are widely used antiretroviral agents belonging to the class of nucleoside reverse transcriptase inhibitors (NRTIs), commonly employed in the treatment of HIV infection. The maximum absorbance (λmax) of Abacavir an d Emtricitabine was found to be 263 nm and 281 nm, respectively. These wavelengths were selected for simultaneous estimation due to their adequate sensitivity and minimal spectral interference. The method was validated in accordance with International Coun cil for Harmonisation (ICH) guidelines. Validation parameters such as linearity, accuracy, precision, robustness, ruggedness, limit of detection (LOD), and limit of quantification (LOQ) were evaluated. The results demonstrated that the method is reliable, reproducible, and suitable for routine quality control analysis. In conclusion, the developed UV – Visible spectrophotometric method is simple, economical, and efficient for the simultaneous estimation of Abacavir and Emtricitabine, and can be effectively us ed in pharmaceutical laboratories for routine analysis.
Zitieren
APA
Pavithra","email":"harichandana.1007@gmail.com","affiliation, N., Reddy","email":"harichandana.1007@gmail.com","affi, N. P., Manju","email":"harichandana.1007@gmail.com","affiliation":", N., Avinash","email":"harichandana.1007@gmail.com","affiliation", N., ujitha","email":"harichandana.1007@gmail.com","affiliation, N. P., Harichandhana","email":"harichandana.1007@gmail.com","affili, N., Suchitra","email":"harichandana.1007@gmail.com","affiliation, N., & chandra","email":"harichandana.1007@gmail.com","aff, N. P. (2026). Analytical Method Development and Validation of Abacavir and Emtricitabine by UV and Visible Spectrophotometry. Future Journal of Pharmaceuticals and Health Sciences, 6(2), 14-24. https://doi.org/10.26452/fjphs.v6i2.554
Vancouver
Pavithra","email":"harichandana.1007@gmail.com","affiliation N, Reddy","email":"harichandana.1007@gmail.com","affi NP, Manju","email":"harichandana.1007@gmail.com","affiliation":" N, Avinash","email":"harichandana.1007@gmail.com","affiliation" N, ujitha","email":"harichandana.1007@gmail.com","affiliation NP, Harichandhana","email":"harichandana.1007@gmail.com","affili N, et al. Analytical Method Development and Validation of Abacavir and Emtricitabine by UV and Visible Spectrophotometry. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(2):14-24. doi:10.26452/fjphs.v6i2.554
BibTeX
@article{Pavithraemailharichandanagmailcomaffiliation2026,
author = {Pavithra","email":"harichandana.1007@gmail.com","affiliation, "name":"Kommala and Reddy","email":"harichandana.1007@gmail.com","affi, "name":"Jammi Pushpasri and Manju","email":"harichandana.1007@gmail.com","affiliation":", "name":"Tallapaka and Avinash","email":"harichandana.1007@gmail.com","affiliation", "name":"Kalpam and ujitha","email":"harichandana.1007@gmail.com","affiliation, "name":"Kothapalli P and Harichandhana","email":"harichandana.1007@gmail.com","affili, "name":"Nalisetty and Suchitra","email":"harichandana.1007@gmail.com","affiliation, "name":"Monapati and chandra","email":"harichandana.1007@gmail.com","aff, "name":"Yadala Prapurna},
title = {Analytical Method Development and Validation of Abacavir and Emtricitabine by UV and Visible Spectrophotometry},
journal = {Future Journal of Pharmaceuticals and Health Sciences},
year = {2026},
volume = {6},
number = {2},
pages = {14--24},
doi = {10.26452/fjphs.v6i2.554}
}
EUVIMED